Would immunization be the same without cross-reactivity?

This video supports the published article Vojtek I, Buchy P, Doherty TM, Hoet B.Would immunization be the same without cross-reactivity? Vaccine. 2019;37(4):539-549. doi: 10.1016/j.vaccine.2018.12.005. In this article, we review the concepts of ‘cross-reactivity’ and ‘cross-protection’ which are both common and important from a public health perspective. Real-world cross-protection data are now available for several vaccines (e.g. those against diseases caused by human papillomavirus and rotavirus). Through this article, we reviewed the growing body of evidence to highlight the full impact of vaccines – beyond vaccine-type disease – that should be taken into consideration when assessing the full value of vaccination programs. With the advent of the next generation of vaccine technologies, we think cross-reactivity might become the solution to creating vaccines against highly antigenically and genetically diverse pathogens.本视频配套的已发表学术论文为：Vojtek I、Buchy P、Doherty TM、Hoet B所著《无交叉反应性的免疫接种是否仍具意义？》，刊载于《疫苗（Vaccine）》2019年第37卷第4期，页码539-549，DOI：10.1016/j.vaccine.2018.12.005。本文首先综述了交叉反应性（cross-reactivity）与交叉保护（cross-protection）的概念，二者均为公共卫生领域常见且重要的研究议题。目前已公开多项疫苗的真实世界交叉保护数据，例如针对人乳头瘤病毒（human papillomavirus）与轮状病毒（rotavirus）所致疾病的相关疫苗。本文通过梳理日益增多的相关研究证据，阐明了疫苗的完整保护效应：其保护范围不止于疫苗对应型别引发的疾病，这一效应在评估疫苗接种项目的整体价值时不容忽视。随着新一代疫苗技术的发展，我们认为交叉反应性有望成为研发针对抗原性与遗传多样性极高的病原体的疫苗的有效解决方案。